Octreotide-Resistant Acromegaly: Challenges and Solutions
Giuliana Corica,1,2 Marco Ceraudo,3 Claudia Campana,1,2 Federica Nista,1,2 Francesco Cocchiara,2 Mara Boschetti,1,2 Gianluigi Zona,3 Diego Criminelli,3 Diego Ferone,1,2 Federico Gatto1 1Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 2Endocrinology Unit, Department of Inter...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-05-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/octreotide-resistant-acromegaly-challenges-and-solutions-peer-reviewed-article-TCRM |
| _version_ | 1818681297518723072 |
|---|---|
| author | Corica G Ceraudo M Campana C Nista F Cocchiara F Boschetti M Zona G Criminelli D Ferone D Gatto F |
| author_facet | Corica G Ceraudo M Campana C Nista F Cocchiara F Boschetti M Zona G Criminelli D Ferone D Gatto F |
| author_sort | Corica G |
| collection | DOAJ |
| description | Giuliana Corica,1,2 Marco Ceraudo,3 Claudia Campana,1,2 Federica Nista,1,2 Francesco Cocchiara,2 Mara Boschetti,1,2 Gianluigi Zona,3 Diego Criminelli,3 Diego Ferone,1,2 Federico Gatto1 1Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 2Endocrinology Unit, Department of Internal Medicine and Medical Specialties (DIMI) and Centre of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa, Italy; 3Neurosurgery Unit, Department of Neurosciences (DINOGMI), IRCCS Ospedale Policlinico San Martino, University of Genoa, Genoa, ItalyCorrespondence: Diego FeroneEndocrinology Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, Genoa 16132, ItalyTel +39 010 3537946Fax +39 010 3537060Email ferone@unige.itAbstract: Acromegaly is a rare and severe disease caused by an increased and autonomous secretion of growth hormone (GH), thus resulting in high circulating levels of insulin-like growth factor 1 (IGF-1). Comorbidities and mortality rate are closely related to the disease duration. However, in most cases achieving biochemical control means reducing or even normalizing mortality and restoring normal life expectancy. Current treatment for acromegaly includes neurosurgery, radiotherapy and medical therapy. Transsphenoidal surgery often represents the recommended first-line treatment. First-generation somatostatin receptor ligands (SRLs) are the drug of choice in patients with persistent disease after surgery and are suggested as first-line treatment for those ineligible for surgery. However, only about half of patients treated with octreotide (or lanreotide) achieve biochemical control. Other available drugs approved for clinical use are the second-generation SRL pasireotide, the dopamine agonist cabergoline, and the GH-receptor antagonist pegvisomant. In the present paper, we revised the current literature about the management of acromegaly, aiming to highlight the most relevant and recent therapeutic strategies proposed for patients resistant to first-line medical therapy. Furthermore, we discussed the potential molecular mechanisms involved in the variable response to first-generation SRLs. Due to the availability of different medical therapies, the choice for the most appropriate drug can be currently based also on the peculiar clinical characteristics of each patient.Keywords: acromegaly, biochemical control, medical therapy, resistance, somatostatin receptor ligands |
| first_indexed | 2024-12-17T10:00:43Z |
| format | Article |
| id | doaj.art-ee2058b7659e43818d561f56127b650c |
| institution | Directory Open Access Journal |
| issn | 1178-203X |
| language | English |
| last_indexed | 2024-12-17T10:00:43Z |
| publishDate | 2020-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-ee2058b7659e43818d561f56127b650c2022-12-21T21:53:18ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2020-05-01Volume 1637939153550Octreotide-Resistant Acromegaly: Challenges and SolutionsCorica GCeraudo MCampana CNista FCocchiara FBoschetti MZona GCriminelli DFerone DGatto FGiuliana Corica,1,2 Marco Ceraudo,3 Claudia Campana,1,2 Federica Nista,1,2 Francesco Cocchiara,2 Mara Boschetti,1,2 Gianluigi Zona,3 Diego Criminelli,3 Diego Ferone,1,2 Federico Gatto1 1Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 2Endocrinology Unit, Department of Internal Medicine and Medical Specialties (DIMI) and Centre of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa, Italy; 3Neurosurgery Unit, Department of Neurosciences (DINOGMI), IRCCS Ospedale Policlinico San Martino, University of Genoa, Genoa, ItalyCorrespondence: Diego FeroneEndocrinology Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, Genoa 16132, ItalyTel +39 010 3537946Fax +39 010 3537060Email ferone@unige.itAbstract: Acromegaly is a rare and severe disease caused by an increased and autonomous secretion of growth hormone (GH), thus resulting in high circulating levels of insulin-like growth factor 1 (IGF-1). Comorbidities and mortality rate are closely related to the disease duration. However, in most cases achieving biochemical control means reducing or even normalizing mortality and restoring normal life expectancy. Current treatment for acromegaly includes neurosurgery, radiotherapy and medical therapy. Transsphenoidal surgery often represents the recommended first-line treatment. First-generation somatostatin receptor ligands (SRLs) are the drug of choice in patients with persistent disease after surgery and are suggested as first-line treatment for those ineligible for surgery. However, only about half of patients treated with octreotide (or lanreotide) achieve biochemical control. Other available drugs approved for clinical use are the second-generation SRL pasireotide, the dopamine agonist cabergoline, and the GH-receptor antagonist pegvisomant. In the present paper, we revised the current literature about the management of acromegaly, aiming to highlight the most relevant and recent therapeutic strategies proposed for patients resistant to first-line medical therapy. Furthermore, we discussed the potential molecular mechanisms involved in the variable response to first-generation SRLs. Due to the availability of different medical therapies, the choice for the most appropriate drug can be currently based also on the peculiar clinical characteristics of each patient.Keywords: acromegaly, biochemical control, medical therapy, resistance, somatostatin receptor ligandshttps://www.dovepress.com/octreotide-resistant-acromegaly-challenges-and-solutions-peer-reviewed-article-TCRMacromegalybiochemical controlmedical therapyresistancesomatostatin receptor ligands |
| spellingShingle | Corica G Ceraudo M Campana C Nista F Cocchiara F Boschetti M Zona G Criminelli D Ferone D Gatto F Octreotide-Resistant Acromegaly: Challenges and Solutions Therapeutics and Clinical Risk Management acromegaly biochemical control medical therapy resistance somatostatin receptor ligands |
| title | Octreotide-Resistant Acromegaly: Challenges and Solutions |
| title_full | Octreotide-Resistant Acromegaly: Challenges and Solutions |
| title_fullStr | Octreotide-Resistant Acromegaly: Challenges and Solutions |
| title_full_unstemmed | Octreotide-Resistant Acromegaly: Challenges and Solutions |
| title_short | Octreotide-Resistant Acromegaly: Challenges and Solutions |
| title_sort | octreotide resistant acromegaly challenges and solutions |
| topic | acromegaly biochemical control medical therapy resistance somatostatin receptor ligands |
| url | https://www.dovepress.com/octreotide-resistant-acromegaly-challenges-and-solutions-peer-reviewed-article-TCRM |
| work_keys_str_mv | AT coricag octreotideresistantacromegalychallengesandsolutions AT ceraudom octreotideresistantacromegalychallengesandsolutions AT campanac octreotideresistantacromegalychallengesandsolutions AT nistaf octreotideresistantacromegalychallengesandsolutions AT cocchiaraf octreotideresistantacromegalychallengesandsolutions AT boschettim octreotideresistantacromegalychallengesandsolutions AT zonag octreotideresistantacromegalychallengesandsolutions AT criminellid octreotideresistantacromegalychallengesandsolutions AT feroned octreotideresistantacromegalychallengesandsolutions AT gattof octreotideresistantacromegalychallengesandsolutions |